In the latest D2C news India update within the fast-evolving D2C beauty and skincare India segment, bootstrapped medical-grade skincare brand Ceuticoz is targeting ₹40 crore in revenue this fiscal, up from ₹26–27 crore last year. The performance places the brand firmly among emerging D2C brands India that are scaling profitably within the Direct-to-consumer India landscape.
Founded by Sukhbir Singh Chimni, Ceuticoz has been EBITDA-positive since inception—an increasingly rare milestone in today’s competitive D2C ecosystem India. As per the founder, the brand is already ahead of its growth targets and expects to cross ₹40 crore in revenue this year, reflecting strong D2C revenue growth and disciplined execution within D2C business India.
Currently, India contributes over 70% of Ceuticoz’s total revenues, making it the core growth engine in its D2C business model India. The company is expanding its dermatologist-led distribution model into tier-2 and tier-3 towns, tapping into rising D2C consumer behavior India trends where demand for science-led, pharmaceutical-grade skincare is accelerating beyond metros. This strategy aligns with broader D2C market trends 2025, where regional penetration and omnichannel D2C strategy are becoming central to brand expansion plans.
Ceuticoz aims to make pharmaceutical-grade, high-quality skincare more accessible and mainstream in smaller towns, addressing a clear affordability and awareness gap. Within D2C industry news, this approach positions the brand among sustainable D2C brands that prioritize product efficacy and professional credibility over excessive marketing spends.
Internationally, the Gulf region is the next priority market, forming a key part of Ceuticoz’s D2C expansion plans. The brand plans to exhibit at Dubai Derma and is building channel partnerships across the GCC. Markets such as Iraq, Vietnam, Nepal, and Thailand are already showing traction, while Canada has recently been added as a new geography. In Canada, Ceuticoz is replicating its professional-channel strategy by targeting dermatologists, aestheticians, and clinical nurses—strengthening its global Direct-to-consumer startup IPO tracker narrative through structured market entry.
On the product front, Ceuticoz has launched seven baby care products and is preparing to introduce four high-potency ampoules next quarter. Doctors already recommend ampoules for delivering high concentrations of active ingredients, and the company expects this to be a significant D2C product launch within the D2C wellness startups and D2C personal care brands categories. By sourcing ingredients from over 23 countries, Ceuticoz reinforces its premium positioning within Premium D2C brands India and science-led D2C brand building stories.
The company anticipates 35% annual growth over the next two to three years and has set a long-term target of crossing ₹100 crore in revenue. While not actively pursuing D2C funding rounds or angel investment D2C at present, the founder has indicated openness to a strategic partner who can add operational or global expansion value beyond capital—reflecting mature D2C investor insights and disciplined capital strategy.
As India’s D2C market news and insights continue to spotlight profitable, bootstrapped growth stories, Ceuticoz stands out among Latest D2C startups for its EBITDA-positive model, tier-2 and tier-3 focus, international scaling, and science-first differentiation. For those tracking the daily digest of D2C news in India, this is a strong example of how focused execution and professional credibility can drive sustainable scale within the fast-growing Direct-to-consumer India ecosystem.
